1. DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway. Issue 6 (24th June 2022) Authors: Shao, Zhulin; Li, Xiaohong; Xu, Xiangjin; Chen, Pin Journal: Drug development research Issue: Volume 83:Issue 6(2022) Page Start: 1373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin. Issue 12 (31st August 2021) Authors: Pei, Yu; Agner, Bue R.; Luo, Bin; Dong, Xiaolin; Li, Dongmei; Liu, Jun; Liu, Lei; Liu, Ming; Lu, Yibing; Nishida, Tomoyuki; Xu, Xiangjin; Mu, Yiming Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 12(2021) Page Start: 2687 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial. (2nd July 2020) Authors: Wang, Wei; Yao, Jun; Guo, Xiaohui; Guo, Yushan; Yan, Chaoli; Liu, Kuanzhi; Zhang, Ying; Wang, Xiaoyue; Li, Hongmei; Wen, Zhongyuan; Wang, Xinling; Li, Shuangqing; Xiao, Xinhua; Liu, Weijuan; Li, Ziling; Zhang, Lihui; Shao, Shiying; Ye, Shandong; Qin, Guijun; Li, Yiming Journal: Current medical research and opinion Issue: Volume 36:Number 7(2020) Page Start: 1107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial. Issue 7 (4th April 2019) Authors: Yang, Wenying; Ma, Jianhua; Hong, Tianpei; Liu, Ming; Miao, Heng; Peng, Yongde; Wang, Changjiang; Xu, Xiangjin; Yang, Tao; Nielsen, Anne M.; Pan, Lili; Liu, Weihong; Zhao, Weigang Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 7(2019) Page Start: 1652 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial. Issue 2 (6th November 2020) Authors: Yang, Wenying; Xu, Xiangjin; Lei, Tao; Ma, Jianhua; Li, Ling; Shen, Jie; Ye, Binqi; Zhu, Sandy; Meinicke, Thomas Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 2(2021) Page Start: 642 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: A randomized placebo‐controlled trial1: 普瑞巴林在中国痛性糖尿病周围神经病变患者治疗中的疗效及安全性:一项随机安慰剂对照试验. Issue 3 (1st November 2017) Authors: Mu, Yiming; Liu, Xiaomin; Li, Quanmin; Chen, Kangning; Liu, Yu; Lv, Xiaofeng; Xu, Xiangjin; Fan, Dongsheng; Shang, Ningxiu; Yang, Ruoyong; Pauer, Lynne; Pan, Changyu Journal: Journal of diabetes Issue: Volume 10:Issue 3(2018) Page Start: 256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. (3rd April 2022) Authors: Lin, Lu; Xu, Xiangjin; Yu, Yunjie; Ye, Hongjiang; He, Xiaoqiong; Chen, Shengping; Chen, Xaingqi; Shao, Zhulin; Chen, Pin Journal: Journal of dermatological treatment Issue: Volume 33:Number 3(2022) Page Start: 1428 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus: A 16-week, multicenter, randomized clinical trial (the FREE study). (June 2020) Authors: Ji, Linong; Gao, Leili; Chen, Liming; Wang, Yangang; Ma, Zhongshu; Ran, Xingwu; Sun, Zilin; Xu, Xiangjin; Wang, Guixia; Guo, Lixin; Shan, Zhongyan Journal: EClinicalMedicine Issue: Volume 23(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model. (March 2018) Authors: Chen, Pin; Shi, Xiaozhi; Xu, Xiangjin; Lin, Yiyang; Shao, Zhulin; Wu, Rongdan; Huang, Lihong Journal: Diabetes research and clinical practice Issue: Volume 137(2018) Page Start: 173 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin. (3rd October 2021) Authors: Chen, Pin; Lin, Lu; Xu, Xiangjin; Zhang, Zhenting; Cai, Wei; Shao, Zhulin; Chen, Shengping; Chen, Xiangqi; Weng, Qiaoling Journal: Journal of dermatological treatment Issue: Volume 32:Number 7(2021) Page Start: 745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗